Scientific article
Open access

Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation

Published inBMC gastroenterology, vol. 10, 71
Publication date2010

BACKGROUND: Hepatitis B immune globulins (HBIG) in combination with nucleos(t)ide analogues (NA) are effectively used for the prevention of hepatitis B virus (HBV) recurrence after liver transplantation (LT). However, associated treatment costs for HBIG are exceedingly high. METHODS: Fresh frozen plasma obtained from blood donors with high anti-HBs levels (hyperimmune plasma, HIP) containing at least 4,500 IU anti-HBs was used as alternative treatment for HBV recurrence prophylaxis post-LT. RESULTS: Twenty-one HBV-related LT recipients received HIP starting at transplantation, followed by long-term combination treatment with NA. Mean follow-up time was 4.5 years (range 0.5-12.6) and each patient received on average 8.2 HIP per year (range 5.8-11.4). Anti-HBs terminal elimination kinetic after HIP administration was 20.6 days (range 13.8-30.9), which is comparable to values reported for commercial HBIG products. All 21 patients remained free of HBV recurrence during follow-up and no transfusion-transmitted infection or other serious complication was observed. Seven patients developed reversible mild transfusion reactions. The cost for one HIP unit was US$140; average yearly HBIG treatment cost was US$1,148 per patient, as compared to US$25,000-100,000 for treatment with commercial HBIG. CONCLUSION: The results of this study suggest that the use of HIP may be a useful and economical approach for the prevention of HBV recurrence post-LT if used in combination with NA. Additional prospective controlled studies in larger populations are needed to confirm these results.

  • Adult
  • Antiviral Agents/therapeutic use
  • Cost-Benefit Analysis
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Hepatitis B/economics/immunology/ prevention & control
  • Hepatitis B Antibodies/adverse effects/economics/ therapeutic use
  • Humans
  • Immunoglobulins/economics/ therapeutic use
  • Liver Transplantation/ immunology
  • Male
  • Middle Aged
  • Plasma
  • Recurrence/prevention & control
  • Treatment Outcome
Citation (ISO format)
BIHL, Florian et al. Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation. In: BMC gastroenterology, 2010, vol. 10, p. 71. doi: 10.1186/1471-230X-10-71
Main files (1)
Article (Accepted version)
ISSN of the journal1471-230X

Technical informations

Creation05/22/2012 3:15:54 PM
First validation05/22/2012 3:15:54 PM
Update time03/14/2023 5:30:26 PM
Status update03/14/2023 5:30:26 PM
Last indexation01/15/2024 11:40:08 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack